{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089563","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.057330+00:00","generated_at":"2026-06-11T17:14:41.362123+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Carisma Q2 net loss $19.9M, cash $117.1M; dosed first patient in CT-0508+KEYTRUDA combo trial","bullets":["Dosed first patient in Phase 1 trial of CT-0508 in combination with KEYTRUDA for HER2-overexpressing solid tumors.","Nominated additional oncology target under Moderna collaboration; total of five nominated targets.","Cash, cash equivalents and marketable securities $117.1M as of June 30, 2023 (down from $139.0M Q1 2023); expected to fund through end of 2024.","Net loss $19.9M for Q2 2023 vs $14.8M for Q2 2022; R&D expenses increased to $18.5M from $14.2M.","Appointed Eric Siegel as General Counsel and Terry Shields as SVP of Human Resources."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089563","json":"https://secwatch.observer/filing/0001104659-23-089563.json","markdown":"https://secwatch.observer/filing/0001104659-23-089563.md","text":"https://secwatch.observer/filing/0001104659-23-089563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923089563/0001104659-23-089563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923089563/tm2322975d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:14:41.362123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54df23164102b69a3c7a4aaa8a2cceb5b0e031ba","claim":"Carisma Therapeutics Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $19.9 million for the second quarter of 2023.","evidence_excerpt":"Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923089563/0001104659-23-089563-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $19.9 million for the second quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}